A Singapore pharmaceutical company built on formulation science, regulatory discipline and partnerships you can check for yourself.
INNORINI PTE. LTD. (UEN 202015523Z) is a Singapore pharmaceutical company incorporated on 4 June 2020 and led by its founder and Managing Director, Rishi Nandiraju, a National University of Singapore Chemical Engineering graduate. Innorini provides pharmaceutical OEM through qualified GMP partners, HSA regulatory affairs and licensed wholesale distribution, and is the exclusive licensee for Nasodine® in Singapore, Malaysia, Brunei and Mauritius.
Rishi Nandiraju founded Innorini in June 2020 and leads the company as Managing Director. He studied Chemical Engineering at the National University of Singapore (NUS) with a second major in the Innovation & Design Programme (iDP), and applies design thinking to every product brief.
His time as an SCDF Rota Commander showed him the physical demands on frontline personnel, which led to Innorini’s first formulation, the Innolyte oral rehydration range. His final-year project, the Innolax range, won the Most Innovative Project Award at the NUS iDP Project Showcase 2024. Today he leads Innorini’s partnerships, including the exclusive Nasodine licence with ASX-listed Firebrick Pharma.
Alongside his degree he gained pharmaceutical manufacturing experience as an R&D intern at Sarvotham Care Limited, and served as a Residential Assistant at NUS Tembusu College from 2021 to 2023.
Rishi’s final-year project, the Innolax range, won the Most Innovative Project Award at the NUS Innovation & Design Programme (iDP) Project Showcase 2024, held at the NUS College of Design and Engineering in April 2024. Innolax Essential and Innolax Detox are psyllium-based formulations designed to support natural bowel movement, and were evaluated in gene-expression studies as part of the project.
NUS project page: Innolax → · NUS CDE news: iDP Project Showcase 2024 →
Each milestone below is drawn from a public record: ACRA, NUS, or Firebrick Pharma’s announcements to the Australian Securities Exchange.
Registered with ACRA as a private company, UEN 202015523Z.
The Innolax range wins at the NUS iDP Project Showcase 2024.
INNORINI-STABICON PTE. LTD. (UEN 202437346M) incorporated; it is the brand on PartyPal’s packaging.
Marketing Representation Agreement signed with Firebrick Pharma (ASX:FRE). From 1 November 2024 Innorini promotes Nasodine® Nasal Spray to GPs, hospital doctors and pharmacists in Singapore.
Nasodine stock distributed to Guardian pharmacies in Singapore, supported by a distribution agreement with DKSH Singapore.
Innorini appointed exclusive licensee for all Nasodine products in Singapore, Malaysia, Brunei and Mauritius, taking over management of the DKSH and Guardian relationships.
Innorini begins promoting Nasodine Throat Spray to Singapore’s government hospitals.
Innorini launches Nasodine Throat Spray in Singapore, the product’s first international market.
Innorini has been an excellent partner for us in Singapore.
His stated aim for the partnership: to “build Nasodine into a trusted household name in Singapore.”
Rishi Nandiraju, Managing Director, Innorini. ASX announcement, 21 January 2026.
| INNORINI PTE. LTD. UEN 202015523Z | Singapore headquarters. OEM and CDMO project management, HSA regulatory affairs, import coordination, licensed wholesale distribution, Special Access Route support and unit-dose packing. Exclusive Nasodine licensee. |
|---|---|
| INNORINI-STABICON PTE. LTD. UEN 202437346M | Consumer health brand “Innorini Stabicon”, used on PartyPal, and the home of Innorini’s private-label supplement work. |
| LYRUS LIFE SCIENCES PTE. LTD. UEN 202144062H | Therapeutic products division. Incorporated in Singapore on 21 December 2021. |
Innorini operates from 1 Clementi Loop, #05-02 Clementi West LogisPark, Singapore 129808, which houses regulatory and commercial operations, incoming quality review, storage and unit-dose packing. Manufacturing takes place at qualified GMP partner sites, not in Singapore. About the Clementi facility →
To provide environmentally friendly and innovative solutions.
Constantly innovate with blue ocean ideas in the realm of pharmaceuticals and nutraceuticals to enhance user wellbeing.
Innorini was built on a simple premise: emerging pharmaceutical brands deserve a partner that handles the whole journey to market, without the minimum runs of large CDMOs or the narrow scope of pure distributors. We sit in that gap, combining GMP manufacturing through our partners with Singapore’s regulatory standing and access to established distribution channels.